Kiniksa Pharmaceuticals International, plc KNSA Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's change in other liabilities?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported change in other liabilities of $6.79M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's change in other liabilities changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's change in other liabilities increased by 105.1% year-over-year, from $3.31M to $6.79M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's change in other liabilities?
- Over 3 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's change in other liabilities has grown at a 214.9% compound annual growth rate (CAGR), from -$535K to $16.7M.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.